Abstract 22 homosexual or narcotic addict patients at risk for acquired immunodeficiency syndrome (AIDS) or with AIDS, were studied for the presence of antiimmunoglobulin antibodies and circulating immune complexes (20 were thrombocytopenic, 6 had AIDS).
Introduction
Individuals at risk for the acquired immunodeficiency syndrome (AIDS):' sexually active homosexuals (1) (2) (3) , narcotic addicts (4), and multiply transfused hemophiliacs (5, 6 ) develop a new syndrome of idiopathic thrombocytopenic purpura (ITP), which is clinically indistinguishable from classic autoimmune thrombocytopenic purpura (ATP) (7). However, immunologic studies Received for publication 20 November 1985 and in revised form 7 February 1986.
1. Abbreviations used in this paper: ADE, adenovirus; AIDS, acquired immunodeficiency syndrome; ATP, autoimmune thrombocytopenic purpura; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HSITP, homosexual ITP; HSV, herpes simplex virus; ITP, idiopathic thrombocytopenic purpura; KLH, keyhole limpet hemocyanin; NITP, narcotic addicts with ITP; PEG, polyethylene glycol; PMSF, phenylmethylsulfonyl fluoride.
(1-4, 6) reveal significant differences between the new syndrome(s) and classic ATP. Thrombocytopenic patients at risk for AIDS have markedly elevated platelet-bound IgG and complement (C3C4) compared with ATP patients, markedly elevated incidence and level of circulating immune complexes (determined by the polyethylene glycol [PEG] precipitation method) compared with ATP patients, and serum antibody against the AIDS-related retrovirus. Recent studies (2) evaluating the immunologic mechanisms involved have suggested that this disorder may be mediated by circulating immune complexes in homosexual ITP (HSITP); and by circulating immune complexes as well as specific antiplatelet 7S IgG in narcotic addicts (NITP) (4).
Our present report describes studies on immune complexes in patients at risk for AIDS and reveals the presence of Ig anti-F(ab')2 antibodies in the serum and circulating immune complexes of these patients.
Methods
Population. The population studied for anti-F(ab')2 antibody included 16 sexually active homosexuals (10 with thrombocytopenia alone, 4 with thrombocytopenia and AIDS [3 with Kaposi's sarcoma, 1 with Pneumocystis carinii pneumonia], 2 with AIDS [Kaposi's sarcoma] and normal platelet counts); 6 narcotic addicts with thrombocytopenia; 7 classic female ATP patients; and 5 control subjects. The clinical manifestations presented by these patients are essentially the same as those described in previous publications (1-4, 7).
Procedures. Viral studies for detection of antigen as well as antibody were performed for Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV), rubeola virus, and adenoviruses (ADE) using standard indirect immunofluorescent techniques.
Antigen-containing platelets or PEG-precipitated immune complexes were washed twice with centrifugation at 3,000 g in 0.01 M phosphatebuffered saline (PBS), pH 7.4, containing I mg/ml bovine serum albumin and spotted on glass slides, which were divided into two groups. One group was treated with 0.1 M glycine buffer, pH 3.0 for 15 min, and rinsed twice with PBS to remove dissociated antibodies. Both treated and untreated fractions were fixed in acetone and tested for viral antigens using fluorescein isothiocyanate-conjugated rabbit antisera specific for each of the moieties to be tested.
Antibody specificities in sera or in immune complex precipitates were tested as follows: Each sample was diluted in 0.1 M glycine buffer, pH 3.0 at 1:2 or 1:8 and heated at 56°C for 30 min to dissociate endogenous complexes. The pH of each sample was adjusted to pH 7.0 and tested for antibody activity. Two standard serologic procedures were used, indirect immunofluorescence antibody staining and immune adherence hemagglutination (8) .
Platelet eluates were prepared from 1 X 108 washed platelets (9) The sensitivity of the IgM assay was 0.5 ng per well.
Affinity purification ofanti-F(ab')2 from serum IgG was accomplished by coupling purified F(ab')2 to a solid-matrix Affi-gel column (Bio-Rad Laboratories, Richmond, CA). Affi-gel 10 was washed on a scintered glass filter with ice-cold isopropanol, followed by ice-cold distilled water, as recommended by the manufacturer. F(ab')2 was dialyzed against 0.1 M 2[(N-morpholino)ethanesulfonic acid] buffer, pH 6.5 containing 0.1 mM phenylmethylsulfonyl fluoride (PMSF) overnight. 1 ml of F(ab')2 (5 mg/ml) was then incubated with 1 ml of packed Affi-gel 10 overnight.
Unattached reactive sites were neutralized with 1 M Tris-HCI buffer, pH 6 .5 for 1 h and then washed. A l-ml column was prepared from a plastic syringe, and IgG applied to the column with the effluent reapplied two times. The column was then washed extensively with 0.1 M NaHCO3, pH 8.0, until the optical density reading of the effluent at 280 sm was zero. Bound antibody was then eluted with 0.1 M glycine buffer, pH 2.5, and the effluent fractions neutralized immediately with NaHCO3. The peak fractions were dialyzed against water, and lyophilized until further use.
Affinity purification ofF(ab')2 from immune complexes was attained with the following procedure: Affi-gel coupled to F(ab')2, as above, was washed with glycine buffer, pH 2.5, containing 0.1 M PMSF until the wash solution had an optical density at 280 um of zero and pH of 2.5.
The isolated immune complex precipitate was dissolved in 0.1 M glycine buffer, pH 2.5, containing protease inhibitors: 0.1 mM PMSF, 5 mM EGTA, and 10 mM benzamidine. The acidified immune complex solution and Affi-gel coupled to F(ab')2 were mixed 1:1 by volume and dialyzed overnight against 0.1 M NaHCO3, pH 8.0, containing protease inhibitors. The pH of the suspension in the dialysis sac should be 8.0.
By this maneuver, the solid-phase F(abV)2 competes for the solubilized anti-F(ab')2 IgG ofthe immune complex as the pH is raised. The contents were then poured into a plastic syringe column and washed with 0.1 M NaHCO3 plus protease inhibitors until the effluent had an optical density reading of zero. The bound anti-F(ab`)2 antibody was then eluted as above witb 0.1 M glycine buffer, pH 2.5, and neutralized with NaHCO3.
Kappa and lambda light chains of affinity-purified F(ab')2 antibody were detected by solid-phase immunoassay using rabbit anti-kappa chain antibody or rabbit anti-lambda chain antibody at a dilution of 1:300 (Calbiochem-Behring Corp., American Hoechst Corp., San Diego, CA), and 1251I-protein A, as in the assay cited above for anti-F(ab')2 reactivity.
Results
The presence of "anti-antibodies" was suggested from preliminary studies designed to analyze platelets and immune complexes for viral antigens, to which they had been exposed, and their respective antibodies. These are cited below. Viral studies of immune complexes. As with the platelet preparations, viral antigens for EBV, CMV, HSV, and rubeola virus were absent on four fixed immune complex preparations of HSITP patients. However, anti-viral antibody analysis of the same immune complexes did reveal antibodies against EBV, CMV, HSV, and rubeola virus, that correlated with the presence of these antibodies in their respective sera (Table I ). No such correlation was noted with preparations from three healthy control subjects whose immune complex preparations were negative in the presence of positive serum titers.
These observations suggested that some immune complexes may be composed ofantibodies directed against other antibodies.
Anti-F(ab')2 IgG antibodies in homosexual patients. When purified IgG from 10 HSITP patients (A-V) and two Kaposi's sarcoma patients with normal platelet counts (E, F) was tested against a panel of F(ab')2 fragments from four HSITP patients (A-D) and two patients with Kaposi's sarcoma alone (E, F) moderate to marked anti-F(ab')2 reactivity was noted with the IgG fractions of five patients (A-I) (Table II) . This was associated with fairly broad reactivity, wherein antibody was directed against autologous as well as allogeneic F(ab')2, and against control as (Table IV) . Patient DD's purified serum IgG was affinity-purified on solid-phase F(ab')2 from patient A. The reactivity of the highly purified anti-F(ab')2 IgG increased its ratio to 9.0. This affinity-purified antibody was shown to have both kappa and lambda light chains. A sixth patient, JJ, had broad reactivity against the panel of 6 F(ab')2 fragments of Table III , with ratios ranging from 2.2 to 2.9 (data not shown).
Absence of anti-F(ab')2 IgG antibodies in ATP patients. In contrast, when the IgG fractions of six thrombocytopenic ATP Specificity ofanti-F(ab')2 IgG antibodies. The broad specificity of anti-F(ab')2 Ig antibodies, noted particularly in homosexual patients, suggested that these were not antiidiotype antibodies. To confirm this suspicion, experiments were performed with two different purified multiple myeloma monoclonal F(ab')2 fragments. Anti-F(ab')2 IgG from patients A and II reacted equally well with both monoclonal F(ab')2 fragments. Anti-F(ab')2 Ig from patient A reacted equally well with both monoclonal F(ab')2 fragments as well as F(ab')2 fragments from patients A and B as well as control H (Table VI) . These data indicate lack of idiotype specificity of anti-F(ab')2 antibodies for F(ab')2 fragments.
Discussion
These data indicate the presence of high titer IgG anti-F(ab')2 antibodies in the sera and immune complexes of thrombocytopenic patients at risk for AIDS, or with AIDS, that correlates (18) , and anti-F(ab')2 antibodies in individuals immunized against keyhole limpet hemocyanin (KLH) (19) .
The anti-IgG antibody found in these patients was not rheumatoid factor (IgM against IgG-Fc), nor IgM anti-IgG, but rather IgG anti-F(ab')2. The reactivity for F(ab')2 was broad with reactivity against control F(ab')2 as well as autologous or homologous F(ab')2 fragments for most of the homosexual patients studied. However, 3 of 12 HSITP and 5 of 6 NITP patients appeared to have limited reactivity against specific F(ab')2 fragments. This suggested the possibility that some ofthese anti-F(ab')2 antibodies might be antiidiotypes. Attempts to demonstrate specificity were unsuccessful, since F(ab')2 fragments from two different purified monoclonal IgG preparations of multiple myeloma patients reacted equally well with different positive reacting anti-F(ab')2 preparations. Nevertheless, since affinity-purified anti-F(ab')2 antibodies were polyclonal, (kappa and lambda light chains), the possibility of specific antiidiotype antibody has not been ruled out. For example, if anti-AIDS-associated retrovirus antibody can be affinity purified, it would be ofinterest to determine whether anti-F(ab')2 antibodies could block binding of anti-AIDS-associated retrovirus antibody to its epitopes on the virus. Indeed, IgG anti-F(ab')2 antibodies with blocking activity against anti-DNA antibody (16, 17) , as well as antitetanus toxoid antibody (17) have recently been reported in patients with SLE; whereas anti-F(ab')2 antibodies of patients with rheumatoid arthritis did not block anti-DNA antibody of SLE patients (16) . In addition, individuals immunized with KLH have anti-F(ab')2 antibodies against anti-KLH antibody in their circulating immune complexes (19) . The etiology of the circulating immune complexes as well as the autoimmune and alloimmune anti-F(ab')2 antibodies in these patients at risk for AIDS, or with AIDS, is not readily apparent. Experimental anti-antibodies have been produced after immunization of rabbits with antigen as well as antigen-antibody complexes, however (20) (21) (22) . It has been postulated that immune complex formation results in unfolding of sites on the autologous IgG molecule that could expose buried antigenic determinants not recognized by the host (20) . Indeed, human IgG anti-F(ab')2 or anti-IgG antibodies have been noted in normal subjects (23, 24) that could be adsorbed out or dissociated with immune complexes (23, 24) , or F(ab')2 fragments (23) , but not with intact IgG (23) . Repeated antigenic stimulation in patients at risk for AIDS could lead to the very high level of circulating immune complexes noted, which in turn may contribute to the formation of anti-F(ab')2 antibodies, thus perpetuating immune complex formation. It is possible that the circulating immune complexes and anti-F(ab')2 result from exposure to the AIDS-associated retrovirus as well as other viruses.
In addition, since AIDS is a disorder of immune regulation, it is likely that these anti-F(ab')2 antibodies, which are present at low levels in some normal control subjects (12, 16, 23) , have lost their immunoregulatory control mechanisms. A disorder of down regulation of anti-F(ab')2 antibody production thus might reflect perturbation of the T cell-B cell network by the AIDSassociated retrovirus. It is possible that some, if not all, of the postulated mechanisms are responsible for the elevated circulating immune complexes and anti-F(ab')2 antibodies in patients at risk for AIDS, or with AIDS.
